This article is more than 5 years old. Information may no longer be current.

Ovarian cancer: Where we are today

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

September is Ovarian Cancer Awareness Month, an educational and fundraising campaign targeting the leading cause of gynecologic cancer deaths.

According to the Ovarian Cancer Research Fund Alliance, ovarian cancer is fifth leading cause of cancer-related death among women, and more than 14,000 women will die of the disease in the U.S. this year.

In conjunction with the awareness month, HemOnc Today compiled a list of six recent updates about treatment, novel investigational drugs and screening.

• The use of aspirin daily may reduce ovarian cancer risk and improve survival after diagnosis. READ MORE.
• The FDA approved bevacizumab (Avastin, Genentech) for use with chemotherapy, followed by bevacizumab as a single agent, for the treatment of women with advanced ovarian cancer who underwent initial surgical resection. READ MORE.
• Oral apatinib (YN968D1, LSK BioPharma) — a novel, small-molecule tyrosine kinase inhibitor that selectively inhibits VEGFR-2 — in combination with etoposide appeared effective with manageable toxicities among women with platinum-resistant or -refractory ovarian cancer. READ MORE.
• Whole-exome sequencing confirmed well-known breast and ovarian cancer gene associations and identified MSH6 and ATM as possible moderate-risk predisposition genes. READ MORE.
• Only 8% of older or disabled women with breast or ovarian cancer who had Medicare and met eligibility criteria underwent testing for BRCA1 and BRCA2 mutations between 2000 and 2014. READ MORE.
• Frontline olaparib (Lynparza; AstraZeneca, Merck) — a first-in-class PARP inhibitor —significantly improved PFS compared with placebo among women with BRCA-mutated advanced ovarian cancer. READ MORE.